Duke University researchers have developed SBI-810, an experimental non-opioid drug that targets the neurotensin receptor 1 and activates only specific pain-relief pathways without triggering addiction or euphoria. In mouse studies, SBI-810 effectively treated various pain conditions including surgical incisions and nerve injuries while preventing common opioid side effects like constipation and tolerance buildup. The compound, which has secured multiple patents and is heading toward human trials, demonstrated superior performance compared to both common opioids and nerve pain medications like gabapentin, without causing sedation or memory problems. With chronic pain affecting one-third of Americans and over 80,000 annual overdose deaths, SBI-810 represents a promising alternative that could provide powerful pain relief through its targeted action on both peripheral and central nervous systems.
Image credit: Kanur Ismail / iStock